Literature DB >> 23592224

Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment.

M C Amato1, V Guarnotta, D Forti, M Donatelli, S Dolcimascolo, C Giordano.   

Abstract

STUDY QUESTION: Is it possible to distinguish metabolically healthy polycystic ovary syndrome (MH-PCOS) from metabolically unhealthy PCOS (MU-PCOS) by simple diagnostic tools such as body mass index (BMI), waist/hip ratio (WHR), at-risk category suggested by Androgen Excess Society (AES) and visceral adiposity index (VAI)? SUMMARY ANSWER: VAI could be an easy and useful tool in clinical practice and in population studies for assessment of MU-PCOS. WHAT IS KNOWN ALREADY: VAI is a good indicator of insulin sensitivity and cardiometabolic risk in oligo-ovulatory women with PCOS. STUDY DESIGN, SIZE, DURATION: We conducted a cross-sectional study of 232 women with PCOS in a university hospital setting. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Anthropometric, hormonal and metabolic parameters were evaluated. An oral glucose tolerance test measured areas under the curve (AUC) for insulin (AUC 2h insulin) and for glucose (AUC 2h glucose). Homeostasis model assessment of insulin resistance (HOMA2-IR), the Matsuda index of insulin sensitivity (ISI), the oral dispositional index (DIo) and VAI were determined. MAIN RESULTS AND THE ROLE OF CHANCE: The prevalence of MU-PCOS according to the different criteria was: BMI, 56.0%; WHR, 18.1%; at-risk criteria of AES, 72.0% and VAI, 34.5%. The likelihood that a woman would exhibit MU-PCOS (except when diagnosed by the WHR criterion) showed a significant positive association with high HOMA2-IR [BMI criterion: (odds ratio (OR): 1.86; 95% confidence interval (CI): 1.43-2.41); risk criteria of AES (OR: 1.86; 95% CI: 1.36-2.56); VAI criterion (OR: 1.45; 95% CI: 1.17-1.80)] and a significant negative association with low ISI Matsuda [BMI criterion: (OR: 0.81; 95% CI: 0.72-0.91); risk criteria of AES (OR: 0.78; 95% CI: 0.69-0.89); VAI criterion (OR: 0.82; 95% CI: 0.71-0.94)]. Only MU-PCOS according to the VAI criterion showed a significant association with low DIo (OR: 0.85; 95% CI: 0.75-0.96); these women also showed a significant association with low luteal progesterone levels (OR: 0.97; 95% CI: 0.95-0.99). LIMITATIONS, REASONS FOR CAUTION: The analysis is limited by the lack of a gold standard definition of metabolic health that would have allowed the execution of a receiver operator characteristic analysis of the four proposed criteria. WIDER IMPLICATIONS OF THE
FINDINGS: The results will facilitate the early recognition of cardiometabolic risk in women with PCOS before they develop overt metabolic syndrome.

Entities:  

Keywords:  PCOS; metabolic assessment; visceral adiposity index

Mesh:

Year:  2013        PMID: 23592224     DOI: 10.1093/humrep/det105

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  12 in total

1.  Distinguishing characteristics of metabolically healthy versus metabolically unhealthy obese adolescent girls with polycystic ovary syndrome.

Authors:  Joon Young Kim; Hala Tfayli; Sara F Michaliszyn; Sojung Lee; Silva Arslanian
Journal:  Fertil Steril       Date:  2016-02-24       Impact factor: 7.329

Review 2.  What do we know about metabolic syndrome in adolescents with PCOS?

Authors:  Derya Akdağ Cırık; Berna Dilbaz
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-03-01

3.  Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.

Authors:  U Durmus; C Duran; S Ecirli
Journal:  J Endocrinol Invest       Date:  2016-11-12       Impact factor: 4.256

4.  Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes.

Authors:  Marco C Amato; Giuseppe Pizzolanti; Vittoria Torregrossa; Gabriella Misiano; Salvatore Milano; Carla Giordano
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

5.  Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability.

Authors:  Valentina Guarnotta; Giulia Di Bella; Giuseppe Pillitteri; Alessandro Ciresi; Carla Giordano
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-26       Impact factor: 5.555

Review 6.  Visceral adiposity index: an indicator of adipose tissue dysfunction.

Authors:  Marco Calogero Amato; Carla Giordano
Journal:  Int J Endocrinol       Date:  2014-04-14       Impact factor: 3.257

7.  Transport of deoxy-D-glucose into lymphocytes of patients with polycystic ovary syndrome.

Authors:  Bożenna Oleszczak; Leszek Szablewski; Monika Pliszka; Olgierd Głuszak; Urszula Stopińska-Głuszak
Journal:  Endocrine       Date:  2014-02-11       Impact factor: 3.633

Review 8.  The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus.

Authors:  Joselyn Rojas; Mervin Chávez-Castillo; Valmore Bermúdez
Journal:  Int J Reprod Med       Date:  2014-12-08

9.  Activation of Systemic Inflammation and Oxidative Stress in Adolescent Girls with Polycystic Ovary Syndrome in Combination with Metabolic Disorders and Excessive Body Weight.

Authors:  Elena Khashchenko; Mikhail Vysokikh; Elena Uvarova; Lyubov Krechetova; Valentina Vtorushina; Tatyana Ivanets; Maria Volodina; Nadezhda Tarasova; Iuliia Sukhanova; Gennady Sukhikh
Journal:  J Clin Med       Date:  2020-05-09       Impact factor: 4.241

10.  Relation between Inflammation, Oxidative Stress, and Macronutrient Intakes in Normal and Excessive Body Weight Adolescent Girls with Clinical Features of Polycystic Ovary Syndrome.

Authors:  Małgorzata Mizgier; Grażyna Jarząbek-Bielecka; Natalia Wendland; Elżbieta Jodłowska-Siewert; Marcin Nowicki; Alicja Brożek; Witold Kędzia; Dorota Formanowicz; Justyna Opydo-Szymaczek
Journal:  Nutrients       Date:  2021-03-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.